Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2310-2511

  Law, Derek ^a,d   Moore, Caroline B ^a   Denning, David W ^b,c  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^d Hyder Environmental   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [4 [4 [[5 (2,4 DIFLUOROPHENYL)TETRAHYDRO 5 (1H 1,2,4 TRIAZOL 1 YLMETHYL)FURAN 3 YL]METHOXY]PHENYL] 1 PIPERAZINYL] PHENYL] 2,4 DIHYDRO 2 (1 ETHYL 2 HYDROXYPROPYL) 3H 1,2,4 TRIAZOLE 3 ONE; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; DRUG BLOOD LEVEL; DRUG ISOLATION; DRUG RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REPRODUCIBILITY; SPECIES DIFFERENTIATION; SPECTROPHOTOMETER; YEAST;

EID: 0030821205     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2310     Document Type: Article

References (12)

1. Baily, G. G., F. M. Perry, D. W. Denning, and B. K. Mandal. 1994. Fluconazole-resistant candidosis in an HIV cohort. AIDS 8:787-792.
2. Denning, D. W. 1995. Can we prevent azole resistance in fungi? Lancet 346:454-455.
3. Espinel-Ingroff, A., C. W. Kish, Jr., T. M. Kerkering, R. A. Fromtling, K. Bartizal, J. N. Galgiani, K. Villareal, M. A. Pfaller, T. Geraden, M. G. Rinaldi, and A. Fothergill. 1992. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J. Clin. Microbiol. 30:3138-3145.
4. Galgiani, J. N., and M. L. Lewis. 1997. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chemother. 41:180-183.
5. Johnson, E. M., K. G. Davey, A. Szekely, and D. W. Warnock. 1995. Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. J. Antimicrob. Chemother. 36:787-793.
6. Johnson, E. M., D. W. Warnock, J. Luker, S. R. Porter, and C. Scully. 1995. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazoie therapy for oral candidosis. J. Antimicrob. Chemother. 35:103-114.
7. Law, D., C. B. Moore, H. M. Wardle, L. A. Ganguli, M. G. L. Keaney, and D. W. Denning. 1994. High prevalence of antifungal resistance in Candida in AIDS. J. Antimicrob. Chemother. 34:659-668.
8. Martinez-Suarez, J. V., and J. L. Rodriguez-Tudela. 1995. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob. Agents Chemother. 39:1512-1516.
9. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M-27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
10. Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. 1996. In vitro and in vivo efficacies of the azole SCH 56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40:1910-1913.
11. Pfaller, M. A., S. Messer, and R. N. Jones. 1997. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235.
12. Rodriguez-Tudela, J. L., and J. V. Martin-Suarez. 1994. Improved medium for fluconazoie susceptibility testing of Candida albicans. Antimicrob. Agents Chemother. 38:45-48.